Excalipoint Therapeutics Inc.(艾科联生物科技）

📍 上海市, China👥 2 employees💰 Last funded Jan 2026
Biotechnology Research
LinkedIn
艾科联生物专注于挖掘T细胞免疫治疗的无限可能，依托自主研发的专有T细胞衔接器（TCE）多抗平台，致力于开发差异化程度更高、临床潜力更强的下一代TCE创新药物。艾科联生物聚焦实体肿瘤和自身免疫疾病治疗等复杂治疗领域，旨在为全球患者提供更优化、更可及的治疗方案。 Excalipoint is committed to unlocking the boundless potential of T-cell based therapeutics. We leverage our unique and proprietary T-cell engager (TCE) multi-specific antibody platform to discover and develop highly differentiated next-generation TCE therapies, for improved treatment options in solid tumor and autoimmune diseases.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Excalipoint Therapeutics Inc.(艾科联生物科技）?
Excalipoint Therapeutics Inc.(艾科联生物科技） has 1 investors on record on gritt.io.
When did Excalipoint Therapeutics Inc.(艾科联生物科技） last raise funding?
The most recent investment in Excalipoint Therapeutics Inc.(艾科联生物科技） recorded on gritt.io was in January 2026.
What industry is Excalipoint Therapeutics Inc.(艾科联生物科技） in?
Excalipoint Therapeutics Inc.(艾科联生物科技） operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Excalipoint Therapeutics Inc.(艾科联生物科技） based?
Excalipoint Therapeutics Inc.(艾科联生物科技） is headquartered in 上海市, China.